Effect of thrombosis-related gene polymorphisms upon oral cancer: A regression analysis

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 4033-4040

  Vylliotis, Antonis ^a   Yapijakis, Christos ^a   Nkenke, Emeka ^b   Nisyrios, Themistoklis ^a   Avgoustidis, Dimitrios ^a   Adamopoulou, Maria ^a   Ragos, Vasilios ^c   Vassiliou, Stavros ^a   Koronellos, Nikolas ^a   Vairaktaris, Eleftherios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Angiotensinconverting enzyme; Angiotensinogen; Coagulation factors; Oral cancer; Regression analysis; Serpine1; SNPs

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSINOGEN; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 5 LEIDEN; CARBOXYPEPTIDASE B; DIPEPTIDYL CARBOXYPEPTIDASE; FATTY ACID BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN;

ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; GENE FREQUENCY; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; THROMBOSIS;

ANGIOTENSIN-CONVERTING ENZYME; ANGIOTENSINOGEN; COAGULATION FACTORS; ORAL CANCER; REGRESSION ANALYSIS; SERPINE1; SNPS;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MOUTH NEOPLASMS; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; THROMBOSIS;

EID: 84884999143     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Baronzio G, Schwartz L, Kiselevsky M, Guais A, Sanders E, Milanesi G, Baronzio M and Freitas I: Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis. Anticancer Res 32(2): 405-414, 2012.
2. Agnelli G and Verso M: Management of venous thromboembolism in patients with cancer. J Thromb Haemost 9(Suppl 1): 316-324, 2011.
3. Sutherland DE, Weitz IC and Liebman HA: Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72(1): 43-52, 2003.
4. Shaib W, Deng Y, Zilterman D, Lundberg B and Saif MW: Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res 30(10): 4261-4264, 2010.
5. Khorana AA: Cancer and coagulation. Am J Hematol 87(Suppl 1): S82-87, 2012.
6. Heit JA: Predicting the risk of venous thromboembolism recurrence. Am J Hematol 87(Suppl 1): S63-67, 2012.
7. Yapijakis C, Bramos A, Nixon AM, Ragos V and Vairaktaris E: The interplay between hemostasis and malignancy: the oral cancer paradigm. Anticancer Res 32(5): 1791-1800, 2012.
8. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D and Bray F: Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380(9856): 1840-1850, 2012.
9. Yako-Suketomo H and Matsuda T: Comparison of time trends in lip, oral cavity and pharynx cancer mortality (1990-2006) between countries based on the WHO mortality database. Jpn J Clin Oncol 40(11): 1118-1119, 2010.
10. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45(4-5): 309-316, 2009.
11. Gonzalez-Moles MA, Scully C and Ruiz-Avila I: Molecular findings in oral premalignant fields: update on their diagnostic and clinical implications. Oral Dis 18(1): 40-47, 2012.
12. McDowell JD: An overview of epidemiology and common risk factors for oral squamous cell carcinoma. Otolaryngol Clin North Am 39: 277-294, 2006.
13. Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, Springer I, Nkenke E, Kessler P and Neukam FW: Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32: 455-457, 2006.
14. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P and Neukam FW: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42: 888-892, 2006.
15. Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW and Patsouris E: Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17: 963-968, 2007.
16. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW and Patsouris E: The 1040 C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor (TAFI) is associated with risk for oral cancer. Am J Hematol 82: 1010-1012, 2007.
17. Vairaktaris E, Yapijakis C, Tsigris C, Vassiliou S, Derka S, Nkenke E, Spyridonidou S, Vylliotis A, Vorris E, Ragos V, Neukam FW and Patsouris E: Association of angiotensinconverting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer. Acta Oncol 46: 1097-1102, 2007.
18. Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, Ragos V, Vylliotis A, Spyridonidou S, Tsigris C, Yannopoulos A, Tesseromatis C, Neukam FW and Patsouris E: Association of matrix metalloproteinase-1 (1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res 27: 459-464, 2007.
19. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, Spyridonidou S, Vorris E, Neukam F and Patsouris E: The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133: 787-791, 2007.
20. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, Vylliotis A, Yapijakis C, Neukam FW and Patsouris E: A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 34(4): 450-455, 2008.
21. Vairaktaris E, Yapijakis C, Vassiliou S, Derka S, Nkenke E, Serefoglou Z, Vorris E, Vylliotis A, Ragos V, Neukam FW and Patsouris E: Association of-1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Anticancer Res 27: 4095-4100, 2007.
22. Masuda J, Nabika T and Notsu Y: Silent stroke: Pathogenesis, genetic factors and clinical implications as a risk factor. Curr Opin Neurol 14: 77-82, 2001.
23. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE and Peake IR: High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 88: 219-222, 1994.
24. Bertina RM: Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 43: 1678-1684, 1997.
25. Caprini JA, Glase CJ, Anderson CB and Hathaway K: Laboratory markers in the diagnosis of venous thromboembolism. Circulation 109: 4-8, 2004.
26. Gluba A, Banach M, Mikhailidis DP and Rysz J: Genetic determinants of cardiovascular disease: The rennin/angiotensin/ aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo 23: 797-812, 2009.
27. Kingsley K, O'Malley S, Ditmyer M and Chino M: Analysis of oral cancer epidemiology in the US reveals state-specific trends: Implications for oral cancer prevention. BMC Public Health 8: 87, 2008.
28. Marney, Ma J, Luther J, Ikizler TA and Brown NJ: Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J Am Soc Nephrol 20: 2246-2252, 2009.
29. Choi SW and Mason JB: Folate and carcinogenesis: An integrated scheme. J Nutr 130: 129-132, 2000.
30. Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komáromi I, Haramura G, Pfliegler G, Mikkola H and Muszbek L: Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 96: 2479-2486, 2000.
31. Fujita M, Hayashi I, Yamashina S, Itoman M and Majima M: Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294: 441-447, 2002.
32. Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, Spyridonidou S, Derka S, Vassiliou S, Nkenke E and Patsouris E: Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 45(3): 247-253, 2009.